Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A phase II Study of TAS-117 in Patients with Advanced Solid Tumors Harboring Germline PTEN -Inactivating Mutations

30 Aug 2022

Abstract excerpt

PTEN acts as a potent tumor suppressor within the PI3K/AKT/mTOR pathway. Germline mutations in the PTEN gene are a hallmark of PTEN hamartoma tumor syndrome, which includes Cowden syndrome, where they appear to elevate lifetime risk of cancer. Targeted AKT directed therapy has been proposed as an effective approach in cancer patients having germline PTEN mutations. The mechanism of action, safety and dosing...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to PI3K/AKT/mTOR signaling in cancer
Share to Ubiquitin and proteasome pathways
Share to Vascular Tumors and Angiosarcomas

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36039910
DOI: 10.2217/fon-2022-0305

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A phase II Study of TAS-117 in Patients with Advanced Solid Tumors Harboring Germline PTEN -Inactivating MutationsPMID 36039910Read ↗

Phase 2 Study of TAS-117 in Advanced Solid Tumors Harboring Phosphatidylinositol 3-Kinase/v-akt Murine Thymoma Viral Oncogene Homolog Gene AberrationsSemantic proximity Read ↗

A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors.Semantic proximity Read ↗

AKT mutant allele-specific activation dictates pharmacologic sensitivities.Semantic proximity Read ↗

Germline PIK3CA and AKT1 mutations in Cowden and Cowden-like syndromes.Semantic proximity Read ↗

Novel Allosteric Inhibitor-Derived AKT Proteolysis Targeting Chimeras (PROTACs) Enable Potent and Selective AKT Degradation in KRAS/BRAF Mutant Cells.Semantic proximity Read ↗

AKT Inhibition in Solid Tumors With AKT1 Mutations.Semantic proximity Read ↗

Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors.Semantic proximity Read ↗

Associations of genetic polymorphisms in pTEN/AKT/mTOR signaling pathway genes with cancer risk: A meta-analysis in Asian population.Semantic proximity Read ↗

Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy.Semantic proximity Read ↗

Association of the PTEN IVS4 (rs3830675) gene polymorphism with reduced risk of cancer: evidence from a meta-analysis.Semantic proximity Read ↗

Effect of AKT1 (p. E17K) Hotspot Mutation on Malignant Tumorigenesis and PrognosisSemantic proximity Read ↗

A phase I study of AZD8186 in combination with docetaxel in patients with PTEN-mutated or PIK3CB-mutated advanced solid tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.